BEAM · Beam Therapeutics Inc. · Webcasts, Transcripts & Audio
$20.90
-0.04 (-0.19%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$2.16B
Shares
103.50M
Volume · Nov 20
3.89M
Avg daily vol (3M)
2.05M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Beam Therapeutics Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Beam Therapeutics Inc. (BEAM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Beam Therapeutics Inc. (BEAM) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-18
Beam Therapeutics Inc. (BEAM) November 18, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Beam Therapeutics Inc. (BEAM) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-27
Beam Therapeutics Inc. (BEAM) Q3 2026 Earnings Call
Revenue
$307,000
▼ 96.8% YoY Diluted EPS
$-1.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Beam Therapeutics Inc. (BEAM) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
Beam Therapeutics Inc. (BEAM) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-20
Beam Therapeutics Inc. (BEAM) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Confident tone
New PKU program (BEAM-304)
Sickle cell disease program
Platform and predictability
Revenue
$114.11M*
▲ 279.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Confident tone
BEAM-101 / BEACON Phase 1/2 in sickle cell disease
ESCAPE antibody-based conditioning platform
BEAM-302 in alpha-1 antitrypsin deficiency (AATD)
Revenue
$14.27M
▼ 17% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Beam Therapeutics Inc. (BEAM) Q4 2021 Earnings Call
Revenue
$51.07M*
▲ 851050% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Beam Therapeutics Inc. (BEAM) Q3 2020 Earnings Call
Revenue
$6,000
▲ 0% YoY Diluted EPS
$-0.69
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 webcasts
Key facts
CIK
1745999
CUSIP
07373V105
13F (30d)
270 filings
247 filers
Visit website
Investor relations